Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Axel, Hanauske"'
Autor:
Axel Hanauske, Assad Chemaissani, Rodryg Ramlau, Jacek Jassem, Wolfgang Schuette, Armando Santoro, S. Adachi, Christian Manegold, Shengyan Hong, J. Blatter
Publikováno v:
Journal of Clinical Oncology. 26:1698-1704
Purpose This multicenter, phase III study compared overall survival (OS) of second-line pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced malignant pleural mesothelioma (MPM). Secondary end points included response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0d138f34abda978d2d345e67fc91e6d
https://doi.org/10.1200/jco.2006.09.9887
https://doi.org/10.1200/jco.2006.09.9887
Autor:
Martin Wilhelm, Karin Weigang-Koehler, Axel Hanauske, Manfred Smetak, Michael Lahn, Ute Ohnmacht, Josef Birkmann
Publikováno v:
Chemotherapy. 54:268-273
Background: Cytotoxic anti-tumor agents like methotrexate or cyclophosphamide have been used in the treatment of autoimmune diseases although the exact mechanism of their immunomodulatory function is unclear. By contrast, molecularly targeted anti-tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac72311c72a07de0c66259a304ba8ce7
https://doi.org/10.1159/000149717
https://doi.org/10.1159/000149717
Autor:
Jantien Wanders, K. Kroon, B.P. Schöffski, Pierre Fumoleau, Jan H.M. Schellens, Alain Ravaud, Axel Hanauske, L. Geoffrois, Markus Borner
Publikováno v:
European Journal of Cancer. 37:1642-1647
A phase II study was performed to evaluate 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT) and leucovorin as first-line chemotherapy in European patients with advanced gastric cancer. From 38 patients, 25 were evaluable for response and 36 for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7c5f8fa05de521f60ba5f58e49213a
https://doi.org/10.1016/s0959-8049(01)00187-3
https://doi.org/10.1016/s0959-8049(01)00187-3
Autor:
Ernst A. de Bruijn, Martin Highley, Peter Harper, Gunther Guetens, Robert A. A. Maes, Allan T. van Oosterom, Herlinde Dumez, Axel Hanauske, Gert De Boeck
Publikováno v:
Seminars in oncology
Blood functions as a mobile tissue in an exchange system, with the remaining body tissue as a stationary phase. The equilibrium among plasma water, plasma proteins, and blood cells is described by models, but little consideration has been given to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32af31d5f291f646df3aaf8d21adebcc
https://doi.org/10.1016/s0093-7754(01)90209-x
https://doi.org/10.1016/s0093-7754(01)90209-x
Autor:
KH Wiese, E Rambusch, Ph. Chollet, Arnold Ganser, M.J. de Vries, Patrick Schöffski, Axel Hanauske
Publikováno v:
Annals of Oncology. 10:1117-1120
We report the case of an unresected, metastatic gastric cancer, which was treated with a very short course of the oral 5-fluorouracil (5-FU) prodrug S-1. The patient had to discontinue chemotherapy during the first treatment cycle due to severe toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::760c0f7e79c861ff46d1a0380d8a5e69
https://doi.org/10.1023/a:1008364601010
https://doi.org/10.1023/a:1008364601010
Autor:
Ast Planting, A.H.G.J Schrijvers, Jean-Pierre Droz, Patrick Schöffski, Axel Hanauske, Jaap Verweij, L Gras, Jantien Wanders, G. Catimel, Dorien M. Schrijvers
Publikováno v:
Annals of Oncology, 10, 119-122. Elsevier Ltd.
Summary Background Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found tne combination of the two drugs to be feasible. The EORTC ECSG performed a multicenter phase II study in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f2c17cae854592bd0c9e79c7f294d3
https://doi.org/10.1023/a:1008360323986
https://doi.org/10.1023/a:1008360323986
Autor:
Axel Hanauske
Publikováno v:
Seminars in Oncology. 29:40-42
Pemetrexed (Alimta; Eli Lilly and Co, Indianapolis, IN) is a novel antifolate/antimetabolite with activity in breast cancer and has well-defined molecular targets, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca4cd1e2e309b9e6043b0287e23b278
https://doi.org/10.1053/sonc.2002.34278
https://doi.org/10.1053/sonc.2002.34278
Autor:
Martin Reck, Tudor Ciuleanu, Coleman K. Obasaju, Nina Karaseva, Susan C. Guba, Shengyan Hong, Egbert F. Smit, Nick Thatcher, Kartik Konduri, Johnetta Blakely, Carla Visseren-Grul, Aleksandra Szczesna, Jacek Jassem, Paul Lorigan, Mircea Dediu, Axel Hanauske, Piotr Serwatowski, Mark A. Socinski
Publikováno v:
Socinski, MA, Smit, E F, Lorigan, P, Konduri, K, Reck, M, Szczesna, A, Blakely, J, Serwatowski, P, Karaseva, N A, Ciuleanu, T, Jassem, J, Dediu, M, Hong, SH, Visseren-Grul, C, Hanauske, A R, Obasaju, C K, Guba, S C & Thatcher, N 2009, ' Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer ', Journal of Clinical Oncology, vol. 27, no. 28, pp. 4787-4792 . https://doi.org/10.1200/JCO.2009.23.1548
Journal of Clinical Oncology, 27(28), 4787-4792. American Society of Clinical Oncology
Journal of Clinical Oncology, 27(28), 4787-4792. American Society of Clinical Oncology
Purpose Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was conducted to compare pemetrexed-carboplatin with etoposide-carboplatin for the trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f04e39a599f28bc6151b6c45b0f29420
https://pubmed.ncbi.nlm.nih.gov/19720897
https://pubmed.ncbi.nlm.nih.gov/19720897
Autor:
T. Graefe, Axel Hanauske, Giuseppe Giaccone, Donald Thornton, E. Yilmaz, B. Kuenen, Michael Lahn, Luna Musib, P. McNealy, K. Weigang-Kohler
Publikováno v:
Annals of Oncology, 20(9), 1565-1575. Oxford University Press
Hanauske, A R, Lahn, M, Musib, L C, Weigang-Koehler, K, Yilmaz, E, Graefe, T, Kuenen, B C, Thornton, D, McNealy, P & Giaccone, G 2009, ' Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer ', Annals of Oncology, vol. 20, no. 9, pp. 1565-1575 . https://doi.org/10.1093/annonc/mdp049
Hanauske, A R, Lahn, M, Musib, L C, Weigang-Koehler, K, Yilmaz, E, Graefe, T, Kuenen, B C, Thornton, D, McNealy, P & Giaccone, G 2009, ' Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer ', Annals of Oncology, vol. 20, no. 9, pp. 1565-1575 . https://doi.org/10.1093/annonc/mdp049
BACKGROUND This phase Ib study evaluated the safety, pharmacokinetics, and activity of enzastaurin either 500 mg once daily (QD) or 250 mg twice daily (b.i.d.) in combination with pemetrexed. PATIENTS AND METHODS Pemetrexed 500 mg/m(2) with folic aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad9177bc742d60b840afab7527ef48e
https://research.vumc.nl/en/publications/87938b30-569b-4505-b06e-8b7283467be8
https://research.vumc.nl/en/publications/87938b30-569b-4505-b06e-8b7283467be8
Autor:
B. Heinrich, F. Theiss, S. Quasthoff, K. Diergarten, M. Herzog, Axel Hanauske, M. Kemmerich, R. Kau, R. Thodtmann, C. Laubenbacher
Publikováno v:
Annals of Oncology. 9:335-337
Summary Background Paclitaxel as single agent has shown marked activity in several malignancies. The aim of the present phase II trial was to determine the activity of paclitaxel/cisplatin in patients with metastatic or recurrent squamous cell carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3f3c225cb5e00b451150eceaf52ef8
https://doi.org/10.1023/a:1008298915121
https://doi.org/10.1023/a:1008298915121